A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics

This study has been completed.
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
First received: January 18, 2013
Last updated: February 1, 2016
Last verified: February 2016
This non-interventional study will assess the occurrence rate of colon, breast and gastric cancer and of malignant melanoma in Turkey and the diagnostic methods and treatments used. Data will be collected over 12 months.

Breast Cancer, Colorectal Cancer, Gastric Cancer, Malignant Melanoma

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective

Resource links provided by NLM:

Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Occurrence rate of colon cancer, defined as new cases recorded in the relevant region in 1 year / population of the region [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Occurrence rate of breast cancer, defined as new cases recorded in the relevant region in 1 year / population of the region [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Occurrence rate of gastric cancer, defined as new cases recorded in the relevant region in 1 year / population of the region [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Occurrence rate of malignant melanoma, defined as new cases recorded in the relevant region in 1 year / population of the region [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Treatment regimens used [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Clinical/demographic patient characteristics at initiation of treatment [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Pathological analysis of tumors [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Incidence/type of surgical interventions [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Treatment regimens used in patients who have progressed to metastatic stage [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Enrollment: 32277
Study Start Date: October 2012
Study Completion Date: October 2015
Primary Completion Date: October 2015 (Final data collection date for primary outcome measure)


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients with colon, breast or gastric cancer or malignant melanoma

Inclusion Criteria:

  • Adult patients, >/= 18 years of age, diagnosed with colon, breast or gastric cancer of malignant melanoma
  • Consent to collection of patient and family history, demographic and disease related information

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01775514

Adana, Turkey, 01330
Adana, Turkey, 01220
Afyon, Turkey, 03200
Ankara, Turkey, 06800
Ankara, Turkey, 06100
Ankara, Turkey, 06200
Ankara, Turkey, 06280
Ankara, Turkey, 06500
Baıkesir, Turkey, 10000
Bursa, Turkey, 16059
Bursa, Turkey, 16040
Denizli, Turkey, 20070
Diyarbakir, Turkey, 21280
Edirne, Turkey, 22770
Erzurum, Turkey, 25050
Gaziantep, Turkey, 27100
Isparta, Turkey, 32260
Istanbul, Turkey, 34890
Istanbul, Turkey, 34020
Istanbul, Turkey, 34300
Istanbul, Turkey, 35100
Istanbul, Turkey, 34000
Izmir, Turkey, 35340
Izmir, Turkey, 35100
Izmir, Turkey, 35110
Kayseri, Turkey, 38039
Konya, Turkey, 42080
Malatya, Turkey, 44280
Sıhhiye, ANKARA, Turkey, 06100
Tokat, Turkey, 60250
Trabzon, Turkey, 61080
Sponsors and Collaborators
Hoffmann-La Roche
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

No publications provided

Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT01775514     History of Changes
Other Study ID Numbers: ML28579 
Study First Received: January 18, 2013
Last Updated: February 1, 2016
Health Authority: Turkey: Ministry of Health

Additional relevant MeSH terms:
Colorectal Neoplasms
Stomach Neoplasms
Colonic Diseases
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Intestinal Diseases
Intestinal Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas
Rectal Diseases
Stomach Diseases

ClinicalTrials.gov processed this record on February 11, 2016